undamentalytics Newsletter

Friedman Paul A: insider trades

Chief executive, Director at 3 companies we cover. 4 open-market purchases and 14 sales not made under a pre-set plan, reported from July 6, 2010 to August 6, 2019.

Would copying Friedman Paul A’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 7, 2010 into $4,376 by November 2, 2026, −5.0% a year. The copy held shares only 19% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $20,229, +4.4% a year (the S&P 500 held throughout made $94,920, +14.8% a year). Beta against the index was 0.22. Twelve months after each report, the average purchase was −24.3% against the S&P 500 (median −30.4%), and 25% beat it. Measured from the trade date, the insider’s own timing, the average was −23.6%. After their sales, the shares moved −15.8% against the index over 12 months on average (a negative figure means selling was the right call); 64% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$50.0k$100k 201020122014201620182020202220242026 $94.9k$20.2k$4.4k
Copying Friedman Paul AS&P 500, same days investedS&P 500, held throughout $10,000 copying Friedman Paul A’s open-market purchases from July 7, 2010, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−5.0%
S&P 500, same days invested
+4.4% (held throughout +14.8%)
Time in shares
19%
Sharpe ratio (S&P 500)
−0.03 (0.81)
Biggest drop (S&P 500)
−88% (−34%)
Market sensitivity (beta)
0.22
Purchases copied
4

Trade by trade

Friedman Paul A: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 +16.1% +11.2% 100% 3 — — Not enough years
Purchases, 6 months after the report 4 −11.6% −21.2% 25% 3 — — Not enough years
Purchases, 12 months after the report 4 −24.3% −30.4% 25% 3 — — Not enough years
Purchases, 12 months after the trade 4 −23.6% −32.6% 25% 3 — — Not enough years
Sales, 3 months after the report 14 −7.4% −10.2% 64% 7 −1.06 0.33 No reliable evidence
Sales, 12 months after the report 14 −15.8% −14.2% 64% 7 −1.33 0.23 No reliable evidence
Sales, 12 months after the trade 14 −16.2% −20.7% 57% 7 −1.28 0.25 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Incyte INCY Chief Executive Officer113July 6, 2010August 6, 2019
Madrigal Pharmaceuticals, Inc. MDGL Chief Executive Officer21June 12, 2018November 23, 2018
Verastem, Inc. VSTM —10December 29, 2014December 29, 2014

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 6, 2019August 2, 2019 INCY Sale $8,268,766 −2.5%+2.5%+7.3%
November 23, 2018November 20, 2018 MDGL Purchase $471,520 +2.9%−31.3%−29.5%
November 19, 2018November 19, 2018 MDGL Purchase $496,000 +13.1%−29.5%−35.8%
June 12, 2018June 11, 2018 MDGL Sale $21,135,784 −29.2%−74.9%−69.4%
November 20, 2017November 16, 2017 INCY Sale $3,000,077 −17.5%−39.0%−45.3%
March 20, 2017March 16, 2017 INCY Sale $7,436,164 −16.0%−54.8%−57.0%
February 27, 2017February 23, 2017 INCY Sale $6,016,000 −4.5%−53.1%−46.4%
November 19, 2015November 17, 2015 INCY Sale $25,612,109 −27.2%−11.9%−19.5%
May 28, 2015May 26, 2015 INCY Sale $21,096,678 +8.5%−25.0%−25.0%
May 26, 2015May 21, 2015 INCY Sale $11,064,921 +5.7%−23.4%−26.7%
February 18, 2015February 13, 2015 INCY Sale $8,918,400 +35.0%−2.6%+2.0%
December 29, 2014December 24, 2014 VSTM Purchase $24,930 +9.3%−80.5%−77.4%
November 7, 2014November 6, 2014 INCY Sale $12,600,269 +5.0%+49.5%+41.0%
February 21, 2014February 20, 2014 INCY Sale $2,118,313 −33.1%+4.3%+12.1%
February 19, 2014February 14, 2014 INCY Sale $50,626,827 −29.6%+12.1%+4.8%
September 12, 2013September 10, 2013 INCY Sale $14,061,765 +27.6%+11.1%+17.1%
May 8, 2012May 7, 2012 INCY Sale $5,076,000 −25.4%−16.5%−21.9%
July 6, 2010July 1, 2010 INCY Purchase $104,257 +39.0%+44.1%+48.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Friedman Paul A traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.